Current trials

Trials in follow-up

Trial

Participants

Target

Accrual

FIELD: Fenofibrate intervention and event lowering in diabetes (CTC-led study)

Patients with Type 2 diabetes

8,000

9,795

LIPID: Long-term intervention with pravastatin in ischaemic disease (CTC-led study)

Patients with a history of coronary heart disease

9,000

9,014

Trials in start-up

Trial

Participants

Target

Accrual

e-PREDICE: Early prevention of diabetes complications in people with hyperglycaemia in Europe and Australia (BIONE and CTC, international study)

Adults with hyperglycaemia

100 (Australia) 3,000 (Int'l)

N/A


Current trials

Trial

Participants

Target

Accrual

FAME1-Eye: Fenofibrate and microvascular events in Type 1 diabetes (CTC-led study)

Adults with Type 1 diabetes and nonproliferative retinopathy

450

6

Performance of closed-loop artificial pancreas at home compared with best available technology (St Vincen's Hospital Melbourne, JDRF, Medtronic, CTC study)

People with Type 1 diabetes:

paediatric cohort

adult cohort

120

160

39

41

REMOVAL: Effects of metformin added to insulin on atheroma progression (CTC, University of Glasgow and NHS-led study)

Adults with Type 1 diabetes at risk of cardiovascular disease

105 (ANZ)

450 (Int'l)

41 (ANZ)

 

T4DM: A randomised, placebo-controlled, Phase III trial adding testosterone to a lifestyle programme to prevent Type 2 diabetes (University of Adelaide and CTC-led study)

Men with prediabetes or newly diagnosed diabetes and low testosterone

1,000

1,007


Trials in follow-up

Trial

Participants

Target

Accrual

TEAMSnet: Using internet and mobile technologies for coordinated diabetes and heart care (University of Melbourne, Fred Hollows Foundation, AMSANT, CERA and CTC study)

Indigenous people from remote and rural Australian communities

600

600

Trials in start-up

Trial

Participants

Target

Accrual

TORPIDO2: Targeted oxygenation in the respiratory care of premature infants at delivery: effects on developmental outcome (CTC-led study)

Neonates born before 29 weeks gestation

1,200

9


Current trials

Trial

Participants

Target

Accrual

LEAP: Lactoferrin evaluation in anaemia in pregnancy (CTC-led study)

Pregnant women with anaemia

900

40

PAEAN: Preventing adverse outcomes of neonatal hypoxic ischaemic encephalopathy (CTC-led study)

Newborn infants with signs of brain damage

300

80


Trials in follow-up

Trial

Participants

Target

Accrual

APTS: Australian placental transfusion study (CTC-led study)

Neonates born before 30 weeks gestation

1,600

1,633

LIFT: Lactoferrin infant feeding trial (CTC-led study)

Infants born weighing under 1,500 g

1,100

1,542